Please use this identifier to cite or link to this item:
|Title:||Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial|
et al, Various
Lee, Ki Hyeong
O'Byrne, Kenneth J.
Tan, Eng Huat
Yang, James Chic-Hsin
Central Clinical School: Medicine
|Publisher:||Oxford University Press|
|Citation:||Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, vol.28, 2, 2017,pp 270-277|
|Department/Unit/Centre:||Central Clinical School: Medicine|
|Disclaimer:||This work has been made available to the staff and students of the University of Sydney for the purposes of research and study only. It constitutes material that is held by the University for the purposes of reporting for HERDC and the ERA. This work may not be downloaded, copied and distributed to any third party .|
|Type:||C1 - Refereed Journal articles|
|Appears in Collections:||University of Sydney Research Outputs|
Items in Sydney Research Online are protected by copyright, with all rights reserved, unless otherwise indicated.